SCHEMBL451909

SCHEMBL451909

COC(=O)c1cc(-c2ccc(F)cc2)c2[nH]c(=O)n(CC(C)(C)O)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.41
MAPK14 Q16539 1/20 0.40
PTGS1 P23219 1/20 0.38
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
ADORA2B P29275 2/20 0.36
GRIN1 Q05586 3/20 0.36
GRIN2B Q13224 3/20 0.36
KDM4E B2RXH2 3/20 0.36
PTPN7 P35236 1/20 0.35
ADORA2A P29274 1/20 0.35
GRM2 Q14416 2/20 0.35
PARP1 P09874 1/20 0.34
MAPT P10636 3/20 0.34
ALDH1A1 P00352 2/20 0.34
GAA P10253 2/20 0.34
HPGD P15428 2/20 0.34
TP53 P04637 1/20 0.34
GLA P06280 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24117024 0.71 PGR (0.55) PIK3CAGRIN1GRIN2B
SCHEMBL24117033 0.71 PGR (0.46) PIK3CAGRIN1GRIN2BGRM2MAPT
SCHEMBL451524 0.69 GRM2 (0.42) PIK3CAMAPK14PTGS1SLC6A4SLC6A3
SCHEMBL462011 0.69 FPR2 (0.44) PIK3CAMAPK14PTGS1SLC6A4SLC6A3
SCHEMBL455504 0.68 MAPK14 (0.40) MAPK14PTGS1SLC6A4SLC6A3KDM4E
SCHEMBL348052 0.66 PTGS1 (0.45) MAPK14PTGS1SLC6A4SLC6A3KDM4E
SCHEMBL18152307 0.66 PTGS1 (0.56) MAPK14PTGS1SLC6A4SLC6A3KDM4E
SCHEMBL20529229 0.66 KDM4E (0.50) KDM4EPARP1MAPTALDH1A1GAA
SCHEMBL2260734 0.65 PTGS1 (0.42) PIK3CAMAPK14PTGS1SLC6A4SLC6A3
SCHEMBL2263369 0.65 PTGS1 (0.49) MAPK14PTGS1SLC6A4SLC6A3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238647-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2016-01-19 US disclosed
EP-2410857-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2014-01-29 EP disclosed
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain MERCK SHARP & DOHME LLC 2012-03-15 US disclosed
EP-2410857-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2012-02-01 EP disclosed
WO-2010111058-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain P2RX3, P2RX1, P2RX2 PIK3CA 1435/4885MAPK14 3418/4885PTGS1 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.